Research & Development: Page 35

  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Choosing the Right EDC/DM Partner: Critical Considerations for Small-toMedium-Sized Life Sciences Organizations

    Whether you are a start-up pharmaceutical or biotech company, a medical devices innovator, or an established organization you want to be equipped with the best possible solution for your study. For small- to medium-sized organizations finding an eClinical partner that is not only competitive but ...

    By Andrew Schachter • June 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    21st Century Trials Demand 21st Century Technology

    The pharmaceutical industry can pride itself on its use of state-of-the art technology in drug discovery using such advances as robotics, molecular modeling, and powerful computational software. Oddly, though, the industry has been slow to take advantage of technology to support clinical operatio...

    By Chris Hall • June 1, 2017
  • clinical trial diversity Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Transforming Trials: Reducing Cost and Risk

    The total sponsor cost per new drug compound approved in the United States now exceeds $2.5 billion, including nearly $1.5 billion for clinical development — an astounding 145% jump in just 15 years, according to the Tufts Center for the Study of Drug Development1. With just 7% of first-in-human ...

    By Dr. Phil Birch • June 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Providing Meaningful Outcomes for Rare Disease Patients and Clinical Developers

    Successful rare disease studies demand different approaches on a number of levels. Early access studies for patients who are living with life altering of rare diseases call for differences regarding study design, regulatory considerations, patient support in study conduct, and an eye to early pha...

    By Richard Scheyer • June 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Speak Out

    Are Early Phase Clinical Trials and Electronic Data Capture Still an Unlikely Pair? At a time when technology is well and truly embedded within people’s everyday lives, the adoption of modern technology within clinical research has been an obvious step forward for the industry. Fifteen years ago,...

    By Dr. George Atiee • June 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Upfront

    Sandoz Names Winners of Healthcare Access Challenge Sandoz, a Novartis division, named the three winners of its inaugural Healthcare Access Challenge (Sandoz HACk). The winners, chosen by a panel of judges at the Wired Health 2017 event in London, identified innovative approaches to address healt...

    By PharmaVoice Team • May 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Innovator's Corner

    Harnessing the Body’s Own Pathways to Silence Genes Douglas Fambrough, Ph.D., President and CEO of Dicerna Pharmaceuticals, talks about his company’s research to develop RNAi therapeutics, a newer approach to drug discovery and development. About 20,000 genes in the human body are deployed in var...

    By Douglas Fambrough • May 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Innovator's Corner

    Developing a New Class of Therapeutics Kevin Lee, Ph.D., CEO of Bicycle Therapeutics, talks about the company’s research to develop a new class of therapeutics using synthetic peptides, small molecules with antibody properties. The war on cancer may soon have a new treatment in its arsenal. Bicyc...

    By Kevin Lee • April 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    HealthTech

    Implant Wirelessly Supplies Power to the Brain Trend Watch: Micro Patches, Implants, and Microscopic 3D Printing Enhance Healthcare A research team at the Department of Electrical and Electronic Information Engineering at Toyohashi University of Technology has developed a wafer-level packaging te...

    By PharmaVoice Team • April 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Speak Out

    At the Forefront of Drug Discovery and Development: Small to Midsize Biotech/Biopharma Companies are the Leaders of Innovation  Today, the innovators of drug discovery and development often are found in the smaller, biotech and biopharma companies around the world. According to a report from HBM...

    By Peter Benton • April 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    Leading from the top Disruption, our experts say in this month’s cover article, is required for the industry to move forward, particularly in light of multiple industry forces. Bernard Munos, senior fellow at FasterCures, Milken Institute, doesn’t like to use the word disruption, because it scare...

    By Taren Grom • March 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Upfront

    Bayer Campaign Aims to Make Saving Lives Something Common Bayer Aspirin’s latest campaign, timed to American Heart Month, aims to raise awareness about heart attacks and about the role of aspirin in reducing the risk of complications. The HeroSmith campaign began in February 2017 in Fort Smith, A...

    By PharmaVoice Team • March 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    HealthTech

    Breakthrough Brain Computer Interface for AR/VR Trend Watch: Patches, baby monitors, BCI, artificial skin, and blockchain move healthcare into the future. Neurable, a developer of brain-computer interface (BCI) technology based on breakthrough neuroscience, has raised a $2 million seed round to b...

    By PharmaVoice Team • March 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Trends in Protocol Development

    Clinical protocols are the framework for a clinical trial. They provide the structure for assessing a potential product’s safety and efficacy. But over the past 15 years, protocols have increased in endpoints, procedures, eligibility criteria, number of CRFs, protocol amendments, and investigativ...

    By Denise Myshko • March 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Ebola Research Update

    In 2014, an outbreak of Ebola in Guinea, West Africa, became a global health crisis within a few months. As the outbreak spread to other countries in West Africa, the crisis strained the countries’ already limited healthcare resources, and spread fear in the United States, as some international h...

    By Denise Myshko • March 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Speak Out

    Calling out Clinical Technology Think about your phone – maybe you are even reading this on it – and you’ll probably have an emotional reaction of some kind. It may or may not be a strong reaction, but odds are there is a certain and specific feeling your phone emotes in you. For something that d...

    By Kristopher E. Sarajian • March 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Upfront

    Trends in Biopharma Innovation Over the last 20 years, a total of 667 innovative biopharmaceuticals have launched in the United States, finds a new report from QuintilesIMS. The characteristics of biopharmaceutical innovation have evolved in some respects over the past two decades. Most notably, ...

    By PharmaVoice Team • Feb. 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Innovator's Corner

    Gene Therapy for Better Sight Kathy High, M.D., President and Chief Scientific Officer at Spark Therapeutics, talks about the company’s gene therapy for inherited retinal diseases. Thanks to a renewed focus on gene therapy, researchers are uncovering new ways to treat diseases where no therapies ...

    By Kathy High • Feb. 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    HealthTech

    Google Trains AI to Spot Diabetic Retinopathy Trendwatch: From eye sight to brain injuries, technology enables better care. A few years ago, Google technologies began working on ways to improve the diabetic retinopathy (DR) screening process, specifically by taking advantage of recent advances in...

    By PharmaVoice Team • Feb. 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Next Generation of Cancer Immunotherapy

    Researchers and drug developers are gaining a better understanding of the immune system and how to better target cancer; as a result, immuno-oncology continues to be a key area of anticancer drug development. Researchers over the last few years have found that the immune system has the capability...

    By Denise Myshko • Feb. 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Update on Zika Research

    First identified in Uganda in 1947, the Zika virus over the past two years has rapidly spread through Asia, the South Pacific, Hawaii, South America, Central America, and the Caribbean. In 2016, active local mosquito-borne transmission began to occur in North America, specifically in Florida and ...

    By Denise Myshko • Feb. 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Rare Disease Day Turns Spotlight on Research

    On the last day in February, hundreds of patients’ groups from around the world will hold a host of activities to raise awareness about rare diseases. The international 10th annual Rare Disease Day, which is coordinated by the European Organization for Rare Diseases (EURORDIS), seeks to help the ...

    By Kim Ribbink • Feb. 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    SHOWCASE FEATURE: Outsourcing: The Outsourcing Big Picture

    Outsourcing is now firmly entrenched in the pharma industry. While pharmaceutical companies have been outsourcing back-office activities for many years now, they are increasingly turning to external partners for research and development activities that traditionally were retained in-house. Today,...

    By PharmaVoice Team • Feb. 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    3-D Outsourcing: The Key to Improved Product Launches

    Put yourself in this situation: You are the director of operations at a growing biotech company. It is either your first product launch or your previous product launches have been slow, inefficient and costly. It is up to you to improve commercialization by streamlining processes and using limite...

    By Steve Devrieze • Feb. 1, 2017
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Speak Out

    Maximizing Patient Recruitment in Rare Disease Research Creating a pharmaceutical develop- ment program for the treatment of a rare disease is challenging. From re-cruiting and retaining patients and investi- gators, through to regulatory uncertainties and limited understanding of the natural his...

    By Jeffrey Zucker • Feb. 1, 2017